دورية أكاديمية
أعرض في EDS

Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology.

التفاصيل البيبلوغرافية
العنوان: Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology.
المؤلفون: Alario AA; Department of Psychiatry and Iowa Neuroscience Institute, University of Iowa Health Care, Iowa City, IA, USA., Niciu MJ; Department of Psychiatry and Iowa Neuroscience Institute, University of Iowa Health Care, Iowa City, IA, USA.
المصدر: Chronic stress (Thousand Oaks, Calif.) [Chronic Stress (Thousand Oaks)] 2021 May 31; Vol. 5, pp. 24705470211014210. Date of Electronic Publication: 2021 May 31 (Print Publication: 2021).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Sage Publications Country of Publication: United States NLM ID: 101701229 Publication Model: eCollection Cited Medium: Internet ISSN: 2470-5470 (Electronic) Linking ISSN: 24705470 NLM ISO Abbreviation: Chronic Stress (Thousand Oaks) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Thousand Oaks, Calif. : Sage Publications, [2017]-
مستخلص: Major depressive disorder (MDD) is one of the leading causes of morbidity and all-cause mortality (including suicide) worldwide, and, unfortunately, first-line monoaminergic antidepressants and evidence-based psychotherapies are not effective for all patients. Subanesthetic doses of the N-methyl-D-aspartate receptor antagonists and glutamate modulators ketamine and S-ketamine have rapid and robust antidepressant efficacy in such treatment-resistant depressed patients (TRD). Yet, as with all antidepressant treatments including electroconvulsive therapy (ECT), not all TRD patients adequately respond, and we are presently unable to a priori predict who will respond or not respond to ketamine. Therefore, antidepressant treatment response biomarkers to ketamine have been a major focus of research for over a decade. In this article, we review the evidence in support of treatment response biomarkers, with a particular focus on genetics, functional magnetic resonance imaging, and neurophysiological studies, i.e. electroencephalography and magnetoencephalography. The studies outlined here lay the groundwork for replication and dissemination.
Competing Interests: Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
(© The Author(s) 2021.)
References: Biol Psychiatry. 2012 Oct 1;72(7):555-61. (PMID: 22521148)
Transl Psychiatry. 2018 Dec 14;8(1):280. (PMID: 30552317)
Chronic Stress (Thousand Oaks). 2018 Jan-Dec;2:. (PMID: 30263977)
Eur Neuropsychopharmacol. 2016 Jun;26(6):994-1003. (PMID: 27133029)
Int J Neuropsychopharmacol. 2013 Mar;16(2):301-11. (PMID: 22676966)
Biol Psychiatry. 2000 Feb 15;47(4):351-4. (PMID: 10686270)
Eur Neuropsychopharmacol. 2020 Sep;38:73-85. (PMID: 32763021)
Cell. 2003 Jan 24;112(2):257-69. (PMID: 12553913)
Biol Psychiatry. 2018 Oct 15;84(8):582-590. (PMID: 29580569)
Biol Psychiatry. 2013 Aug 15;74(4):250-6. (PMID: 22840761)
Hum Brain Mapp. 2020 May;41(7):1699-1710. (PMID: 32115848)
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Apr 20;99:109838. (PMID: 31843628)
J Affect Disord. 2013 Feb 15;145(1):115-9. (PMID: 22871531)
Clin EEG Neurosci. 2018 Sep;49(5):306-315. (PMID: 29224411)
Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Mar;5(3):354-363. (PMID: 31928949)
Am J Psychiatry. 2019 May 1;176(5):401-409. (PMID: 30922101)
Front Psychiatry. 2020 Jun 10;11:519. (PMID: 32655423)
Hum Brain Mapp. 2019 Sep;40(13):3940-3950. (PMID: 31179620)
J Affect Disord. 2019 May 15;251:162-169. (PMID: 30925267)
Neuropsychopharmacology. 2010 Jun;35(7):1415-22. (PMID: 20393460)
Psychiatry Res. 2009 Sep 30;169(2):132-8. (PMID: 19709754)
Mol Psychiatry. 2010 Aug;15(8):810-5. (PMID: 19255578)
Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Oct;2(7):566-574. (PMID: 29034354)
Int J Neuropsychopharmacol. 2020 Dec 29;23(12):791-798. (PMID: 32726408)
Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Jan;5(1):45-55. (PMID: 31495712)
Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Jul 3;:. (PMID: 32900657)
J Affect Disord. 2019 Dec 1;259:15-20. (PMID: 31437695)
Neuropsychopharmacology. 2017 May;42(6):1210-1219. (PMID: 27604566)
J Affect Disord. 2021 Jun 1;288:210-216. (PMID: 33965843)
J Clin Pharm Ther. 2007 Oct;32(5):415-28. (PMID: 17875106)
IEEE Trans Biomed Eng. 2019 Jun;66(6):1668-1679. (PMID: 30369433)
Psychiatry Res Neuroimaging. 2019 Jan 30;283:64-66. (PMID: 30551012)
Transl Psychiatry. 2020 Jul 30;10(1):260. (PMID: 32732915)
Eur Neuropsychopharmacol. 2019 Apr;29(4):501-508. (PMID: 30819549)
J Psychopharmacol. 2017 Dec;31(12):1570-1577. (PMID: 29039254)
Neuroimage Clin. 2018 Jul 05;20:92-101. (PMID: 30094160)
Front Psychiatry. 2020 Aug 18;11:820. (PMID: 33013493)
Biol Psychiatry. 2012 Dec 1;72(11):e27-8. (PMID: 22771240)
Neuropsychopharmacology. 2020 May;45(6):975-981. (PMID: 31896116)
J Psychopharmacol. 2021 Feb;35(2):168-177. (PMID: 32643995)
Nature. 2018 Feb 14;554(7692):317-322. (PMID: 29446381)
Int J Neuropsychopharmacol. 2021 May 18;24(5):383-391. (PMID: 33249434)
Mol Psychiatry. 2020 Sep 14;:. (PMID: 32929215)
Neuropsychopharmacology. 2017 Dec;42(13):2482-2492. (PMID: 28492279)
J Psychopharmacol. 2013 Jul;27(7):651-4. (PMID: 23676198)
Brain Behav. 2020 Aug;10(8):e01674. (PMID: 32621379)
Biol Psychiatry. 2009 Feb 15;65(4):289-95. (PMID: 18822408)
J Affect Disord. 2021 Jan 15;279:239-249. (PMID: 33074143)
Biol Psychiatry. 2012 Jun 1;71(11):996-1005. (PMID: 22036038)
Science. 2012 Oct 5;338(6103):68-72. (PMID: 23042884)
Neuropsychopharmacology. 2020 May;45(6):982-989. (PMID: 31995812)
J Affect Disord. 2020 Dec 1;277:831-841. (PMID: 33065824)
Neuropsychopharmacology. 2020 Jul;45(8):1398-1404. (PMID: 32252062)
Am J Psychiatry. 2017 Jul 1;174(7):695-696. (PMID: 28669202)
Int J Neuropsychopharmacol. 2018 Aug 1;21(8):740-747. (PMID: 29668918)
Transl Psychiatry. 2015 Feb 17;5:e509. (PMID: 25689570)
Psychiatry Res Neuroimaging. 2016 Aug 30;254:56-66. (PMID: 27362845)
Mol Psychiatry. 2019 Jul;24(7):1040-1052. (PMID: 29487402)
Psychiatr Serv. 2014 Aug 1;65(8):977-87. (PMID: 24789696)
Biol Psychiatry. 2016 May 1;79(9):765-775. (PMID: 25837427)
J Affect Disord. 2021 Jan 1;278:515-518. (PMID: 33017679)
معلومات مُعتمدة: R00 AA024142 United States AA NIAAA NIH HHS
فهرسة مساهمة: Keywords: electroencephalography; functional magnetic resonance imaging; genetics; glutamate; ketamine; magnetoencephalography; major depressive disorder; treatment resistant depression
تواريخ الأحداث: Date Created: 20210623 Latest Revision: 20221026
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8186113
DOI: 10.1177/24705470211014210
PMID: 34159281
قاعدة البيانات: MEDLINE
الوصف
تدمد:2470-5470
DOI:10.1177/24705470211014210